Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 138.27M P/E - EPS this Y 18.80% Ern Qtrly Grth -
Income -35.48M Forward P/E -3.98 EPS next Y 65.40% 50D Avg Chg 6.00%
Sales 70.99M PEG -0.05 EPS past 5Y - 200D Avg Chg -31.00%
Dividend N/A Price/Book N/A EPS next 5Y 74.40% 52W High Chg -71.00%
Recommedations 1.70 Quick Ratio 0.53 Shares Outstanding 112.65M 52W Low Chg 37.00%
Insider Own 8.94% ROA -11.29% Shares Float 82.58M Beta -0.24
Inst Own 77.13% ROE - Shares Shorted/Prior 3.21M/3.20M Price 1.24
Gross Margin 87.84% Profit Margin -49.99% Avg. Volume 695,608 Target Price 3.75
Oper. Margin -12.65% Earnings Date May 9 Volume 205,013 Change 2.07%
About OptiNose, Inc.

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

OptiNose, Inc. News
05/03/24 Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
05/02/24 Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know
04/25/24 Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
04/06/24 OptiNose (NASDAQ:OPTN) shareholders have endured a 87% loss from investing in the stock five years ago
04/04/24 Optinose to Present at the Needham Virtual Healthcare Conference
03/15/24 XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
03/10/24 US$3.00: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest Results
03/08/24 OptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Call Transcript
03/08/24 OptiNose Full Year 2023 Earnings: EPS Beats Expectations
03/07/24 Q4 2023 OptiNose Inc Earnings Call
03/07/24 OptiNose Inc (OPTN) Reports Decline in 2023 Revenue Amidst Preparations for Potential XHANCE ...
03/07/24 OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates
03/07/24 Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
02/29/24 Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
02/15/24 Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?
01/18/24 Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
12/06/23 Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
11/22/23 Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
11/17/23 Owning 47% shares,institutional owners seem interested in OptiNose, Inc. (NASDAQ:OPTN),
11/11/23 OptiNose, Inc. (NASDAQ:OPTN) Q3 2023 Earnings Call Transcript
OPTN Chatroom

User Image astroflyery1 Posted - 1 day ago

$OPTN I can encourage everyone to read the well thought discussion below from two of our OGs on this board. (@zoomlik and @CrayP) Both have provided very helpful information and kept the morale high here in the recent days. Thanks to both!

User Image neebie Posted - 1 day ago

$OPTN @zoomlik I can only see you in my camera. Are you everywhere? just kidding

User Image Salahadin666 Posted - 1 day ago

$OPTN up 13% and still absurdly cheap and mis priced.

User Image Porki Posted - 1 day ago

$IINN the production readiness is a good sign. It’s the same thing that $OPTN did right before they received their approval. Should be soon

User Image zoomlik Posted - 1 day ago

$OPTN Here is my revised revenue and GAAP earnings projections 2024 Revenue $78M Loss of $27M 2025 Rev $107M Loss of $2M 2026 Rev $120M Profit of $11M

User Image astroflyery1 Posted - 1 day ago

$OPTN Long overdue upside movement.

User Image JPstocksPremium Posted - 1 day ago

$OPTN 👀

User Image Invest2live Posted - 1 day ago

$OPTN excellent value

User Image astroflyery1 Posted - 2 days ago

$OPTN Institutional ownership is very high. I think a potential buyout should not be far away.

User Image zoomlik Posted - 2 days ago

$OPTN More xhance —> less surgery —> less money for ENT This label expansion will be most prescribed by allergists and Primary Care that don’t do surgeries

User Image zoomlik Posted - 2 days ago

$OPTN My rev assumptions for 2024 Q1 $15M (already stated) Q2 $21M Q3 $23M Q4 $25M Avg price Q1 $195 Q2 $250 Q3,$250 Q4 $250 Total prescripts Q1 76k Q2 84k Q3 92k Q4 100k Cash burn in 2024 $20M Plus Aadditional Short term cash obligations from Q4 2023 of $14M

User Image meistermell Posted - 3 days ago

$OPTN

User Image superdude42 Posted - 3 days ago

$OPTN Should we be expecting earnings around May 9-10? We already know they are bringing in more cash than expected. I think regardless of your position, this is only going to go up until earnings (then crash back to 0.80, ha!)

User Image Salahadin666 Posted - 3 days ago

$OPTN big seller must be off shorting Starbucks or CVS. not seeing block volume of past several days

User Image zoomlik Posted - 3 days ago

$OPTN When they explicitly guided $300M+ revenue , they implicitly guided for NET GAAP profit of $150M in 2028. Which is based on going after 10%’of market with 75 reps Equity should be $3B today !!!

User Image JPstocksPremium Posted - 3 days ago

$OPTN added

User Image zoomlik Posted - 3 days ago

$OPTN Seller has taken a break this morning !!

User Image Bornjever Posted - 3 days ago

$LYRA $OPTN hoping our team wins but hope OPTN picks up pace

User Image buymoremakemore Posted - 04/30/24

$OPTN could this pop on earnings?

User Image zoomlik Posted - 04/30/24

$OPTN Whoever has a dialogue with IR, could you please have them reiterate guidance of $300M+ and more importantly what that translates to expected GAAP operating profit (my math says $170M profit a year)

User Image zoomlik Posted - 04/30/24

$OPTN They should have raised $25M on approval at say $1.25 a share They need that $25M to get to breakeven . Now they need to issue double shares or more shares

User Image Salahadin666 Posted - 04/30/24

$OPTN sure didn’t see this behaving like crap after approval. Trading as if they offered a big secondary and diluted. Still not understanding the why here?

User Image Invest2live Posted - 04/30/24

$OPTN excellent value; anything below 1 dollar is great; 1.25+ coming soon.

User Image zoomlik Posted - 04/30/24

$OPTN Adding today

User Image ZUBI Posted - 04/30/24

$OPTN [email protected]

User Image zoomlik Posted - 04/30/24

$OPTN Anyone has any thoughts on major risks here, we have not talked about

User Image zoomlik Posted - 04/30/24

$OPTN There is prob something very wrong here that Ian missing. I will keep adding though

User Image astroflyery1 Posted - 04/30/24

$OPTN At this point, please allow me to say: WTF

User Image zoomlik Posted - 04/29/24

$OPTN Licensing PCP ends being acquired theory

User Image astroflyery1 Posted - 04/29/24

$OPTN I would like to nominate Mr. Morgan, who is CIO of Velan Capital to the board of directors at OptiNose Inc.

Analyst Ratings
HC Wainwright & Co. Buy Apr 29, 24
Lake Street Buy Mar 18, 24
HC Wainwright & Co. Buy Mar 18, 24
HC Wainwright & Co. Buy Mar 11, 24
Lake Street Buy Aug 21, 23
Piper Sandler Overweight Aug 11, 23
BMO Capital Outperform Nov 14, 22
Cantor Fitzgerald Overweight Mar 5, 20
Cowen & Co. Outperform Dec 18, 19
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Mahmoud Ramy A Chief Executive Offi.. Chief Executive Officer Jan 31 Sell 1.31 52,875 69,266 548,387 02/01/24
Mahmoud Ramy A Chief Executive Offi.. Chief Executive Officer Dec 15 Sell 1.15 11,114 12,781 509,728 12/20/23
Marino Michael F III Chief Legal Officer.. Chief Legal Officer & Corp Sec Dec 15 Sell 1.15 5,005 5,756 333,511 12/20/23
Marino Michael F III Chief Legal Officer.. Chief Legal Officer & Corp Sec Jan 13 Sell 1.77 5,241 9,277 180,353 01/17/23
Miller Peter K Chief Executive Offi.. Chief Executive Officer Jan 13 Sell 1.77 29,664 52,505 853,384 01/17/23
Marino Michael F III Chief Legal Officer.. Chief Legal Officer & Corp Sec Dec 15 Sell 1.69 2,751 4,649 185,594 12/19/22
Janis Michele Acting Chief Financi.. Acting Chief Financial Officer Dec 15 Sell 1.69 1,015 1,715 48,927 12/19/22
Clavelli Victor M Chief Commercial Off.. Chief Commercial Officer Dec 15 Sell 1.69 3,208 5,422 199,955 12/19/22
Miller Peter K Chief Executive Offi.. Chief Executive Officer Dec 15 Sell 1.69 15,253 25,778 883,048 12/19/22
Mahmoud Ramy A President and COO President and COO Mar 16 Sell 2.11 8,219 17,342 195,124 03/17/22
Marino Michael F III Chief Legal Officer.. Chief Legal Officer & Corp Sec Mar 16 Sell 2.11 4,617 9,742 149,545 03/17/22
Goldan Keith A. Chief Financial Offi.. Chief Financial Officer Mar 16 Sell 2.11 4,617 9,742 141,726 03/17/22
Clavelli Victor M Chief Commercial Off.. Chief Commercial Officer Mar 16 Sell 2.11 5,705 12,038 189,693 03/17/22
Miller Peter K Chief Executive Offi.. Chief Executive Officer Mar 16 Sell 2.11 25,974 54,805 880,826 03/17/22
Mahmoud Ramy A President and COO President and COO Sep 17 Sell 2.79 12,499 34,872 281,765 09/17/21